330 related articles for article (PubMed ID: 32325491)
1. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Perez C; Botta C; Zabaleta A; Puig N; Cedena MT; Goicoechea I; Alameda D; San José-Eneriz E; Merino J; Rodríguez-Otero P; Maia C; Alignani D; Maiso P; Manrique I; Lara-Astiaso D; Vilas-Zornoza A; Sarvide S; Riillo C; Rossi M; Rosiñol L; Oriol A; Blanchard MJ; Rios R; Sureda A; Martin J; Martinez R; Bargay J; de la Rubia J; Hernandez MT; Martinez-Lopez J; Orfao A; Agirre X; Prosper F; Mateos MV; Lahuerta JJ; Blade J; San-Miguel JF; Paiva B
Blood; 2020 Jul; 136(2):199-209. PubMed ID: 32325491
[TBL] [Abstract][Full Text] [Related]
2. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
[TBL] [Abstract][Full Text] [Related]
3. Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair.
Aarts CEM; Hiemstra IH; Béguin EP; Hoogendijk AJ; Bouchmal S; van Houdt M; Tool ATJ; Mul E; Jansen MH; Janssen H; van Alphen FPJ; de Boer JP; Zuur CL; Meijer AB; van den Berg TK; Kuijpers TW
Blood Adv; 2019 Nov; 3(22):3562-3574. PubMed ID: 31738831
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.
Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y
Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
6. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
[No Abstract] [Full Text] [Related]
7. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
[TBL] [Abstract][Full Text] [Related]
8. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.
Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M
Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100
[TBL] [Abstract][Full Text] [Related]
9. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
10. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells.
Seddon A; Hock B; Miller A; Frei L; Pearson J; McKenzie J; Simcock J; Currie M
J Dermatol Sci; 2016 Aug; 83(2):124-30. PubMed ID: 27160951
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
13. CD45
Mao FY; Zhao YL; Lv YP; Teng YS; Kong H; Liu YG; Wu XL; Hao CJ; Chen W; Duan MB; Han B; Ma Q; Wang TT; Peng LS; Zhang JY; Cheng P; Su CY; Fu XL; Zou QM; Guo G; Guo XL; Zhuang Y
Cell Death Dis; 2018 Jul; 9(7):763. PubMed ID: 29988030
[TBL] [Abstract][Full Text] [Related]
14. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
15. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
16. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses.
Kontaki E; Boumpas DT; Tzardi M; Mouzas IA; Papadakis KA; Verginis P
Autoimmunity; 2017 May; 50(3):170-181. PubMed ID: 28276713
[TBL] [Abstract][Full Text] [Related]
17. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
19. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
Sheng IY; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan TD; Rini BI; Garcia JA; Grivas P; Ornstein MC
Target Oncol; 2020 Apr; 15(2):211-220. PubMed ID: 32207064
[TBL] [Abstract][Full Text] [Related]
20. Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice.
Kawano T; Shimamura M; Nakagami H; Kanki H; Sasaki T; Mochizuki H
PLoS One; 2019; 14(5):e0215482. PubMed ID: 31048856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]